BridgeBio Pharma Inc.
BBIO | NASDAQ
$75.80
+$0.85 (+1.13%)
Nov 2, 2026, 12:21 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -20.18 | -9.53 | -10.22 | -2.27 | -4.28 | -17.34 |
PEG Ratio | -0.64 | 0.35 | -0.57 | 0.16 | 0.88 | -0.27 |
PS Ratio | 30.05 | 23.01 | 706.43 | 14.47 | 34.54 | 1.02K |
PB Ratio | -7.27 | -3.48 | -4.85 | -0.90 | -2.77 | 144.90 |
P/FCF Ratio | -33.75 | -9.79 | -12.42 | -2.64 | -4.41 | -20.60 |
P/OCF Ratio | -33.83 | -9.81 | -12.45 | -2.68 | -4.84 | -20.99 |
OCF/S Ratio | -88.81 | -234.66 | -5.67K | -540.25 | -714.23 | -4.85K |
Debt / Equity Ratio | -1.31 | -1.18 | -1.28 | -1.37 | -1.98 | 8.56 |
Quick Ratio | 2.52 | 4.67 | 3.32 | 4.52 | 6.58 | 6.72 |
Current Ratio | 2.62 | 4.67 | 3.32 | 4.52 | 6.58 | 6.72 |
Asset Turnover | 0.54 | 0.24 | 0.02 | 0.12 | 0.07 | 0.01 |
Interest Coverage | -10.72 | -5.97 | -7.47 | -6.37 | -12.33 | -12.94 |
Return on Equity | 35.12% | 36.50% | 47.49% | 38.35% | 64.63% | -774.92% |
Return on Assets | -77.92% | -58.28% | -117.72% | -77.23% | -55.54% | -63.78% |
Return on Invested Capital | -108.46% | -77.07% | -149.35% | -101.37% | -65.33% | -77.38% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 94.37% | 98.25% | 73.71% | 95.58% | 95.53% | 100% |
Net Profit Margin | -145.26% | -241.44% | -6.91K% | -619.70% | -806.90% | -5.44K% |
Pretax Profit Margin | -146.39% | -244.34% | -7.02K% | -624.17% | -841.20% | -6.13K% |
Operating Profit Margin | -113.35% | -267.22% | -6.53K% | -659.65% | -827.12% | -5.75K% |
FCF Margin | -89.03% | -235.09% | -5.69K% | -548.39% | -783.44% | -4.94K% |
EBITDA Margin | -134.73% | -196.86% | -6.08K% | -511.85% | -765.73% | -5.67K% |
Add to Watchlist
Select watchlists to add or remove BBIO